Oral Abstract Session
Glomerular Diseases: Clinical Trial Results
October 24, 2026 | 04:30 PM - 06:00 PM
Location: Mile High Ballroom 4A, Convention Center
Session Description
Oral Abstract Session
Learning Pathway(s)
- Glomerular Diseases
Moderators
Presentations
Safety and Efficacy of Inebilizumab in IgG4-Related Disease: Subgroup Analysis from MITIGATE
Zanubrutinib in Phospholipase A2 Receptor (PLA2R)-Associated Primary Membranous Nephropathy (PMN): Updated Results of a Phase 2/3, Multicenter, Randomized, Open-Label Study
Spatial Transcriptomics Reveals Sparsentan-Associated Remodelling of Complement-Active Renal Niches in IgAN
Crovalimab for Adults/Adolescents with Atypical Hemolytic Uremic Syndrome: Phase 3 COMMUTE-a Trial
Off-the-Shelf Anti-CD19 Chimeric Antigen Receptor (CAR)-T Cell Therapy with Less-Intensive Fludarabine-Free Conditioning in Lupus Nephritis: Phase 1 Safety and Efficacy
Curing Lupus Nephritis: Stable Drug-Free Remission After an Intensified B-Cell Depletion Regimen as Compared with Standard of Care: Results from the INTONATE Randomized Trial
Preliminary Data from PrisMN, a Phase 2 Study Evaluating the Safety and Efficacy of Budoprutug, an Investigational Low-Fucosylated Anti-CD19 Monoclonal Antibody (mAb), in Patients with Primary Membranous Nephropathy (PMN)
Evaluation of Safety, Tolerability, and Efficacy of MZE829 in Adults with APOL1-Mediated Kidney Disease (HORIZON Study)
Pegcetacoplan for 76 Weeks Maintains Proteinuria Reduction and Stabilizes Kidney Function in C3 Glomerulopathy or Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)